FRANKFURT (Reuters) - A class of treatments known as antibody-drug conjugates (ADC) combine cancer-tracking proteins with powerful cell toxins. The therapies are getting a fresh start as dozens of drugmakers test a record number of new compounds in people.
Nearly 20 years after the first ADC, Pfizer's Mylotarg, was approved, developers say they are now getting a handle on the technology that was long seen as an elegant concept, but one that presented many clinical challenges.
Already a subscriber? Log in.
Limited time offer:
Just RM5 per month.
Cancel anytime. No ads. Auto-renewal. Unlimited access to the web and app. Personalised features. Members rewards.
Follow us on our official WhatsApp channel for breaking news alerts and key updates!